As per the agreement, Proteros is expected to deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.
Proteros CEO Torsten Neuefeind said that this partnership will build on a long standing and successful relationship.